GERNGERON CORP

Nasdaq geron.com


$ 4.36 $ -0.07 (-1.47 %)    

Wednesday, 26-Jun-2024 14:50:49 EDT
QQQ $ 479.77 $ 0.17 (0.04 %)
DIA $ 391.31 $ 1.20 (0.31 %)
SPY $ 544.95 $ 1.35 (0.25 %)
TLT $ 93.27 $ -0.29 (-0.31 %)
GLD $ 212.65 $ -1.54 (-0.72 %)
$ 4.52
$ 4.43
$ 4.36 x 3,612
$ 4.37 x 300
$ 4.28 - $ 4.44
$ 1.64 - $ 5.34
9,156,831
na
2.73B
$ 0.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-28-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 07-31-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-16-2018 12-31-2017 10-K
27 11-01-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-01-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-03-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 03-11-2015 12-31-2014 10-K
39 11-05-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-initiates-coverage-on-geron-with-overweight-rating-announces-price-target-of-9

Barclays analyst Carter Gould initiates coverage on Geron (NASDAQ:GERN) with a Overweight rating and announces Price Target ...

 barclays-initiates-coverage-on-geron-with-overweight-rating-announces-price-target-of-9

Barclays initiates coverage on Geron (NASDAQ:GERN) with a Overweight rating and announces Price Target of $9.

 stifel-maintains-buy-on-geron-raises-price-target-to-7

Stifel analyst Stephen Willey maintains Geron (NASDAQ:GERN) with a Buy and raises the price target from $6 to $7.

 fda-approves-gerons-first-commercial-drug-competes-with-bristol-myers-squibbs-blood-cancer-drug

FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusi...

 needham-maintains-buy-on-geron-raises-price-target-to-6

Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and raises the price target from $5 to $6.

 wedbush-reiterates-outperform-on-geron-maintains-7-price-target

Wedbush analyst Robert Driscoll reiterates Geron (NASDAQ:GERN) with a Outperform and maintains $7 price target.

 reported-earlier-fda-approves-gerons-rytelo-imetelstat-a-novel-telomerase-inhibitor-for-treating-lower-risk-mds-in-adults-with-transfusion-dependent-anemia

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless...